Back to Search
Start Over
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
- Source :
- The Lancet. 401:747-761
- Publication Year :
- 2023
- Publisher :
- Elsevier BV, 2023.
- Subjects :
- General Medicine
Subjects
Details
- ISSN :
- 01406736
- Volume :
- 401
- Database :
- OpenAIRE
- Journal :
- The Lancet
- Accession number :
- edsair.doi...........eff0f5b3f079585021cebd8eccc46ca1
- Full Text :
- https://doi.org/10.1016/s0140-6736(23)00022-3